TNXP Tonix Pharmaceuticals Holding Corp.
Healthcare$12.77+0.00%ClosedMarket Cap: $203.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.77
P/S
11.60
EV/EBITDA
-0.13
DCF Value
$24.42
FCF Yield
-65.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.6%
Operating Margin
-861.2%
Net Margin
-839.5%
ROE
-67.7%
ROA
-57.1%
ROIC
-66.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.9M | 69.0% | $-41.5M | $-40.2M | $— | — |
| Q4 null | $5.4M | 71.3% | $-48.3M | $-46.9M | $— | — |
| FY null | $13.1M | 34.7% | $-125.7M | $-124.0M | $— | — |
| Q3 null | $3.3M | 58.4% | $-33.1M | $-32.0M | $— | — |
| Q2 null | $2.0M | -63.8% | $-28.3M | $-28.3M | $— | — |
| Q1 null | $2.4M | 61.2% | $-16.1M | $-16.8M | $— | — |
| Q4 null | $2.6M | 54.2% | $-22.5M | $-22.1M | $— | — |
| FY null | $10.1M | 23.1% | $-136.7M | $-130.0M | $— | — |
| Q3 null | $2.8M | 44.9% | $-15.6M | $-14.2M | $— | — |
| Q2 null | $2.2M | -52.5% | $-18.4M | $-78.8M | $— | — |
| Q1 null | $2.5M | 33.1% | $-21.4M | $-14.9M | $— | — |
| Q4 2023 | $3.8M | -2.1% | $-27.3M | $-27.3M | $-6,178.26 | — |